Celgene Corporation (CELG)
-NasdaqGS 123.50 May 21, 4:00PM EDT
| Prev Close: | 123.50 |
|---|
| Open: | N/A |
|---|
| Bid: | 122.18 x 100 |
|---|
| Ask: | 124.46 x 300 |
|---|
| 1y Target Est: | 134.22 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | 25-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 58.53 - 131.82 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 3,222,160 |
|---|
| Market Cap: | 51.51B |
|---|
| P/E (ttm): | 37.57 |
|---|
| EPS (ttm): | 3.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Tue, May 21)
- [$$] Credits & Debits | cfoeditors@wsj.comat The Wall Street Journal(Tue, May 21)
- Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Opportunities in Hepatitis C and Genomic TechnologiesWall Street Transcript(Tue, May 21)
- Are These The Ultimate Growth And Value Plays?StreetAuthority Network(Tue, May 21)
- Midday Glance: Biotechnology companiesAP(Tue, May 21)
- Early Glance: Biotechnology companiesAP(Tue, May 21)
- Celgene, Visa, Apple: Rob Bartolo's Likes, Dislikesat Investor's Business Daily(Mon, May 20)
- Cramer: A Pile of Simply Horrendous Adviceat TheStreet(Mon, May 20)
- Celgene Corporation (CELG): Today's Featured Health Care Winnerat TheStreet(Fri, May 17)
- Bypassing Biotechs and Focusing on the Overlooked Medical Device Space: An Expert Portfolio Manager Discusses His Contrarian Approach to InvestingWall Street Transcript(Fri, May 17)
- Today’s 3 Worst Stocksat Motley Fool(Thu, May 16)
- Stocks Close Lower; Dell Little Changed After Earningsat Investor's Business Daily(Thu, May 16)
- [video] Stock Pops & Dropsat CNBC(Thu, May 16)
- Wall Street Turns Down At The Bell; Celgene Sells Offat Investor's Business Daily(Thu, May 16)
- Gilead Drug For Leukemia Shows Success In Early Trialat Investor's Business Daily(Thu, May 16)
Key Statistics
| Forward P/E (1 yr): | 17.90 |
|---|
| P/S (ttm): | 9.04 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.43 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 1.01 |
|---|
Business Summary
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries.
View More